Has the risk of colorectal cancer in inflammatory bowel disease decreased?

World Journal of Gastroenterology

Volumn 19, Issue 43, 2013, Pages 7561-7568

  Andersen, Nynne Nyboe ^a   Jess, Tine ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

Colorectal cancer; Crohn's disease; Inflammatory bowel disease; Risk; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; MESALAZINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER RISK; CHEMOPROPHYLAXIS; COLORECTAL CANCER; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DISEASE SURVEILLANCE; ENTERITIS; FAMILY HISTORY; GENETIC PREDISPOSITION; HAZARD RATIO; HUMAN; META ANALYSIS (TOPIC); PRIMARY SCLEROSING CHOLANGITIS; STANDARDIZED INCIDENCE RATIO; ULCERATIVE COLITIS;

COLORECTAL CANCER; CROHN'S DISEASE; INFLAMMATORY BOWEL DISEASE; RISK; ULCERATIVE COLITIS;

AGE OF ONSET; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; HEREDITY; HUMANS; PEDIGREE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84888119184     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i43.7561     Document Type: Article

References (60)

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535 [PMID: 11247898 DOI: 10.1136/gut.48.4.526]
2. Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 2004; 19: 287-293 [PMID: 14984375 DOI: 10.1111/j.1365-2036.2004.01858.x]
3. Kraus S, Arber N. Inflammation and colorectal cancer. Curr Opin Pharmacol 2009; 9: 405-410 [PMID: 19589728 DOI: 10.1016/j.coph.2009.06.006]
4. Rhodes JM, Campbell BJ. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med 2002; 8: 10-16 [PMID: 11796261 DOI: 10.1016/ S1471-4914(01)02194-3]
5. Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012; 143: 375-381. e1, quiz e13-14 [PMID: 22522090 DOI: 10.1053/j.gastro.2012.04.016]
6. Crohn BB, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Amer J Med Sci 1925; 170: 220-228 [DOI: 10.1097/00000441-192508010-00006]
7. Bargen JA. Chronic ulcerative colitis associated with malignant disease. 1928. Dis Colon Rectum 1994; 37: 727-730 [PMID: 8026242 DOI: 10.1007/BF02054420]
8. de Dombal FT. Ulcerative colitis. Epidemiology and aetiology, course and prognosis. Br Med J 1971; 1: 649-650 [PMID: 4926950 DOI: 10.1136/bmj.1.5750.649]
9. Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated metaanalysis of population-based cohort studies. Inflamm Bowel Dis 2013; 19: 789-799 [PMID: 23448792 DOI: 10.1097/ MIB.0b013e31828029c0]
10. Mooiweer E, Baars JE, Lutgens MW, Vleggaar F, van Oijen M, Siersema PD, Kuipers EJ, van der Woude CJ, Oldenburg B. Disease severity does not affect the interval between IBD diagnosis and the development of CRC: results from two large, Dutch case series. J Crohns Colitis 2012; 6: 435-440 [PMID: 22398065 DOI: 10.1016/j.crohns.2011.09.014]
11. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228-1233 [PMID: 2215606 DOI: 10.1056/ NEJM199011013231802]
12. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001; 91: 854-862 [PMID: 11241255 DOI: 10.1002/1097-0142(20010215)91: 4<854::AIDCNCR1073> 3.0.CO;2-Z]
13. Söderlund S, Brandt L, Lapidus A, Karlén P, Broström O, Löfberg R, Ekbom A, Askling J. Decreasing time-trends of colorectal cancer in a large cohort of patients with in-flammatory bowel disease. Gastroenterology 2009; 136: 1561-1567; quiz 1818-1819 [PMID: 19422077 DOI: 10.1053/ j.gastro.2009.01.064]
14. Lakatos L, Mester G, Erdelyi Z, David G, Pandur T, Balogh M, Fischer S, Vargha P, Lakatos PL. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 2006; 12: 205-211 [PMID: 16534422 DOI: 10.1097/01.MIB.0000217770.21261.ce]
15. Jess T, Loftus EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Schleck CD, Tremaine WJ, Melton LJ, Munkholm P, Sandborn WJ. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology 2006; 130: 1039-1046 [PMID: 16618397 DOI: 10.1053/j.gastro.2005.12.037]
16. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a populationbased cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004; 2: 1088-1095 [PMID: 15625654 DOI: 10.1016/S1542-3565(04)00543-9]
17. Palli D, Trallori G, Bagnoli S, Saieva C, Tarantino O, Ceroti M, d'Albasio G, Pacini F, Amorosi A, Masala G. Hodgkin' s disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000; 119: 647-653 [PMID: 10982757 DOI: 10.1053/gast.2000.16487]
18. Jess T, Horváth-Puhó E, Fallingborg J, Rasmussen HH, Jacobsen BA. Cancer Risk in Inflammatory Bowel Disease According to Patient Phenotype and Treatment: A Danish Population-Based Cohort Study. Am J Gastroenterol 2013 Aug 27; Epub ahead of print [PMID: 23978954 DOI: 10.1038/ ajg.2013.249]
19. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012; 10: 639-645 [PMID: 22289873 DOI: 10.1016/j.cgh.2012.01.01]
20. Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, Brixi H, Gornet JM, Altwegg R, Beau P, Duclos B, Bourreille A, Faivre J, Peyrin-Biroulet L, Fléjou JF, Carrat F. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013; 145: 166-175. e8 [PMID: 23541909 DOI: 10.1053/j.gastro.2013.03.044]
21. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 2006; 23: 1097-1104 [PMID: 16611269 DOI: 10.1111/j.1365-2036.2006.02854.x]
22. Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TI. Increased risk of intestinal cancer in Crohn's disease: a metaanalysis of population-based cohort studies. Am J Gastroenterol 2005; 100: 2724-2729 [PMID: 16393226 DOI: 10.1111/ j.1572-0241.2005.00287.x]
23. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology 2012; 143: 382-389 [PMID: 22609382 DOI: 10.1053/j.gastro.2012.04.054]
24. Langholz E. Relative or relevant risk? Gastroenterology 2012; 143: e20, author reply e20-e21 [PMID: 23000225 DOI: 10.1053/j.gastro.2012.09.039]
25. Heuschen UA, Hinz U, Allemeyer EH, Stern J, Lucas M, Autschbach F, Herfarth C, Heuschen G. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001; 120: 841-847 [PMID: 11231938 DOI: 10.1053/gast.2001.22434]
26. Haskell H, Andrews CW, Reddy SI, Dendrinos K, Farraye FA, Stucchi AF, Becker JM, Odze RD. Pathologic features and clinical significance of "backwash" ileitis in ulcerative colitis. Am J Surg Pathol 2005; 29: 1472-1481 [PMID: 16224214]
27. Farraye FA, Odze RD, Eaden J, Itzkowitz SH, McCabe RP, Dassopoulos T, Lewis JD, Ullman TA, James T, McLeod R, Burgart LJ, Allen J, Brill JV. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138: 738-745 [PMID: 20141808 DOI: 10.1053/j.gastro.2009.12.037]
28. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P, Fairclough PD, Woodhouse CR. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59: 666-689 [PMID: 20427401 DOI: 10.1136/gut.2009.179804]
29. Baars JE, Kuipers EJ, van Haastert M, Nicolaï JJ, Poen AC, van der Woude CJ. Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, longterm survey. J Gastroenterol 2012; 47: 1308-1322 [PMID: 22627504 DOI: 10.1007/s00535-012-0603-2]
30. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 31-39 [PMID: 2047887 DOI: 10.1055/ s-2008-1040420]
31. Olsson R, Danielsson A, Järnerot G, Lindström E, Lööf L, Rolny P, Rydén BO, Tysk C, Wallerstedt S. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100: 1319-1323 [PMID: 2013375]
32. Rasmussen HH, Fallingborg JF, Mortensen PB, Vyberg M, Tage-Jensen U, Rasmussen SN. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn' s disease. Scand J Gastroenterol 1997; 32: 604-610 [PMID: 9200295 DOI: 10.3109/00365529709025107]
33. Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, Kaplan GG. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011; 53: 1590-1599 [PMID: 21351115 DOI: 10.1002/ hep.24247]
34. Broomé U, Lindberg G, Löfberg R. Primary sclerosing cholangitis in ulcerative colitis--a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 1992; 102: 1877-1880 [PMID: 1587406]
35. Broomé U, Löfberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-1408 [PMID: 7590655]
36. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54 [PMID: 12085034 DOI: 10.1067/mge.2002.125367]
37. Braden B, Halliday J, Aryasingha S, Sharifi Y, Checchin D, Warren BF, Kitiyakara T, Travis SP, Chapman RW. Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2012; 10: 303-308 [PMID: 22037429 DOI: 10.1016/j.cgh.2011.10.020]
38. Thackeray EW, Charatcharoenwitthaya P, Elfaki D, Sinakos E, Lindor KD. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011; 9: 52-56 [PMID: 20920596 DOI: 10.1016/j.cgh.2010.09.020]
39. Marchesa P, Lashner BA, Lavery IC, Milsom J, Hull TL, Strong SA, Church JM, Navarro G, Fazio VW. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997; 92: 1285-1288 [PMID: 9260790]
40. Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999; 94: 1643-1649 [PMID: 10364038]
41. Sokol H, Cosnes J, Chazouilleres O, Beaugerie L, Tiret E, Poupon R, Seksik P. Disease activity and cancer risk in inflammatory bowel disease associated with primary scle-rosing cholangitis. World J Gastroenterol 2008; 14: 3497-3503 [PMID: 18567077 DOI: 10.3748/wjg.14.3497]
42. Claessen MM, Lutgens MW, van Buuren HR, Oldenburg B, Stokkers PC, van der Woude CJ, Hommes DW, de Jong DJ, Dijkstra G, van Bodegraven AA, Siersema PD, Vleggaar FP. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 2009; 15: 1331-1336 [PMID: 19229982 DOI: 10.1002/ibd.20886]
43. Torres J, Pineton de Chambrun G, Itzkowitz S, Sachar DB, Colombel JF. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34: 497-508 [PMID: 21692821 DOI: 10.1111/j.1365-2036.2011.04753.x]
44. Askling J, Dickman PW, Karlén P, Broström O, Lapidus A, Löfberg R, Ekbom A. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001; 120: 1356-1362 [PMID: 11313305 DOI: 10.1053/ gast.2001.24052]
45. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-459 [PMID: 14762782 DOI: 10.1053/j.gastro.2003.11.010]
46. Herrinton LJ, Liu L, Fireman B, Lewis JD, Allison JE, Flowers N, Hutfless S, Velayos FS, Abramson O, Altschuler A, Perry GS. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology 2009; 137: 502-511 [PMID: 19445944 DOI: 10.1053/j.gastro.2009.04.063]
47. Castaño-Milla C, Chaparro M, Gisbert JP. Has the risk of developing colorectal cancer in patients with ulcerative colitis been overstated? A meta-analysis. Gastroenterology 2013; 142: s-251[abstract] Available from: URL: http://www.gastrojournal. org/article/S0016-5085%2812%2960944-5/abstract
48. Jess T, Frisch M, Simonsen J. Trends in overall and causespecific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol 2013; 11: 43-48 [PMID: 23022699 DOI: 10.1016/j.cgh.2012.09.026]
49. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999; 116: 602-609 [PMID: 10029619]
50. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345-1353 [PMID: 15929768 DOI: 10.1111/j.1572-0241.2005.41442.x]
51. Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 2011; 106: 731-736 [PMID: 21407180 DOI: 10.1038/ajg.2011.50]
52. Jess T, Loftus EV, Velayos FS, Winther KV, Tremaine WJ, Zinsmeister AR, Scott Harmsen W, Langholz E, Binder V, Munkholm P, Sandborn WJ. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007; 102: 829-836 [PMID: 17222314 DOI: 10.1111/j.1572-0241.2007.01070.x]
53. Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 367-371 [PMID: 17206695 DOI: 10.1002/ibd.20074]
54. Nguyen GC, Gulamhusein A, Bernstein CN. 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol 2012; 107: 1298-304; quiz 1297, 1305 [PMID: 22751467 DOI: 10.1038/ajg.2012.198]
55. van Schaik FD, van Oijen MG, Smeets HM, van der Heijden GJ, Siersema PD, Oldenburg B. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012; 61: 235-240 [PMID: 21602529 DOI: 10.1136/gut.2011.237412]
56. Pasternak B, Svanström H, Schmiegelow K, Jess T, Hviid A. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol 2013; 177: 1296-1305 [PMID: 23514635 DOI: 10.1093/aje/kws375]
57. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 2010; 105: 1604-1609 [PMID: 20104215 DOI: 10.1038/ajg.2009.745]
58. Onizawa M, Nagaishi T, Kanai T, Nagano K, Oshima S, Nemoto Y, Yoshioka A, Totsuka T, Okamoto R, Nakamura T, Sakamoto N, Tsuchiya K, Aoki K, Ohya K, Yagita H, Watanabe M. Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitisassociated carcinogenesis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G850-G859 [PMID: 19179628 DOI: 10.1152/ ajpgi.00071.2008]
59. Baars JE, Looman CW, Steyerberg EW, Beukers R, Tan AC, Weusten BL, Kuipers EJ, van der Woude CJ. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol 2011; 106: 319-328 [PMID: 21045815 DOI: 10.1038/ajg.2010.428]
60. Andersen NN, Basit S, Svanström S, Pasternak B, Caspersen S, Munkholm P, Hviis A, Jess T. Tumor necrosis factoralpha antagonists and malignancy in inflammatory bowel disease [abstract]. J Crohns Colitis 2012 [DOI: 10.1016/ S1873-9946(12)60451-6]